Healthcare Intelligence
Pharma Clinical Development
Real-time intelligence, expert analysis, and verified research for the Pharma Clinical Development industry. Stay ahead in 3 minutes a day.
Stay ahead of Pharma Clinical Development in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
Pfizer's Danuglipron Shows 6.9% Weight Loss in Phase 2b Obesity Trial
Pfizer's oral GLP-1 drug danuglipron achieved 6.9% weight reduction at highest dose in mid-stage trial, competing with Novo and Lilly.
Read full articleFDA Approves Cobenfy, First New Schizophrenia Drug in Over 30 Years
Bristol Myers Squibb's Cobenfy wins FDA approval as first schizophrenia treatment with novel mechanism in decades.
Read full articleModerna Cuts R&D Spending by $1.1B, Discontinues 5 Programs
Moderna slashes research budget and halts five clinical programs to focus on respiratory vaccines and oncology pipeline.
Read full articleAstraZeneca's Dato-DXd Fails Phase 3 Lung Cancer Trial
AstraZeneca and Daiichi Sankyo's Dato-DXd misses primary endpoint in TROPION-Lung01 study for non-small cell lung cancer.
Read full articleNovartis Halts Development of Branaplam After Safety Concerns
Novartis discontinues branaplam development following peripheral neuropathy cases in Huntington's disease trial.
Read full articleRoche's Vabysmo Shows Superior Vision Gains in Diabetic Eye Disease
Roche's Vabysmo demonstrates better visual acuity improvements versus Eylea in Phase 3 diabetic macular edema trials.
Read full articleGSK's Jemperli Wins FDA Approval for Endometrial Cancer
FDA approves GSK's Jemperli in combination with chemotherapy as first-line treatment for primary advanced endometrial cancer.
Read full articleSanofi Partners with Orano Med for Lead-212 Radiopharmaceuticals
Sanofi enters $320M deal with Orano Med to develop next-generation radioligand therapies using lead-212 isotope.
Read full articlePfizer's Danuglipron Shows 6.9% Weight Loss in Phase 2b Obesity Trial
Pfizer's oral GLP-1 drug danuglipron achieved 6.9% weight reduction at highest dose in mid-stage trial, competing with Novo and Lilly.
Read full articleFDA Approves Cobenfy, First New Schizophrenia Drug in Over 30 Years
Bristol Myers Squibb's Cobenfy wins FDA approval as first schizophrenia treatment with novel mechanism in decades.
Read full articleModerna Cuts R&D Spending by $1.1B, Discontinues 5 Programs
Moderna slashes research budget and halts five clinical programs to focus on respiratory vaccines and oncology pipeline.
Read full articleAstraZeneca's Dato-DXd Fails Phase 3 Lung Cancer Trial
AstraZeneca and Daiichi Sankyo's Dato-DXd misses primary endpoint in TROPION-Lung01 study for non-small cell lung cancer.
Read full articleNovartis Halts Development of Branaplam After Safety Concerns
Novartis discontinues branaplam development following peripheral neuropathy cases in Huntington's disease trial.
Read full articleRoche's Vabysmo Shows Superior Vision Gains in Diabetic Eye Disease
Roche's Vabysmo demonstrates better visual acuity improvements versus Eylea in Phase 3 diabetic macular edema trials.
Read full articleGSK's Jemperli Wins FDA Approval for Endometrial Cancer
FDA approves GSK's Jemperli in combination with chemotherapy as first-line treatment for primary advanced endometrial cancer.
Read full articleSanofi Partners with Orano Med for Lead-212 Radiopharmaceuticals
Sanofi enters $320M deal with Orano Med to develop next-generation radioligand therapies using lead-212 isotope.
Read full articleStay ahead of Pharma Clinical Development in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.